Northwest Biotherapeutics (NWBO) Other Non-Current Assets (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly Other Non-Current Assets came in at $354000.0 in Q1 2026, down 3.54% year-on-year from $367000.0 in Q1 2025, and down 0.56% quarter-over-quarter from $356000.0 in Q4 2025.
Northwest Biotherapeutics (NWBO) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $354000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 3.54% year-over-year to $354000.0 in Q1 2026; TTM through Mar 2026 was $354000.0, a 3.54% decrease from a year earlier, with the FY2025 full-year figure at $356000.0, down 2.47% from the prior year.
- Other Non-Current Assets retreated to $354000.0 in Q1 2026 per NWBO's latest filing, from $356000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $374000.0 in Q3 2024 and bottomed at $339000.0 in Q3 2022.
- The 5-year median for Other Non-Current Assets is $361000.0 (2023), against an average of $358529.4.
- Across the five-year window, Other Non-Current Assets sank 68.71% in 2022 and advanced 5.56% in 2023, its largest moves.
- Year by year, Other Non-Current Assets stood at $345000.0 in 2022, then rose by 4.64% to $361000.0 in 2023, then climbed by 1.11% to $365000.0 in 2024, then declined by 2.47% to $356000.0 in 2025, then decreased by 0.56% to $354000.0 in 2026.
- Per Business Quant, the three latest NWBO Other Non-Current Assets figures stand at $354000.0 (Q1 2026), $356000.0 (Q4 2025), and $358000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,023.69 Bn | 1,023.69 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 468.59 Bn | 463.80 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 123.01 Bn | 115.76 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 70.29 Bn | 61.53 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 63.33 Bn | 63.33 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.70 Bn | 50.52 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Northwest Biotherapeutics | 275.76 Mn | 273.98 Mn | - | 354,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 354,000.00 |
| Dec 31, 2025 | 356,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 367,000.00 |
| Dec 31, 2024 | 365,000.00 |
| Sep 30, 2024 | 374,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Mar 31, 2024 | 363,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | 357,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 362,000.00 |
| Dec 31, 2022 | 345,000.00 |
| Sep 30, 2022 | 339,000.00 |
| Jun 30, 2022 | 342,000.00 |
| Mar 31, 2022 | 349,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Jun 30, 2021 | 1.09 Mn |